AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15845499 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of tetravalent polysaccharide vaccine for children </=18 months old
Number of subjects: 0
Study 15845499 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-dependent increases in postvaccination IgG levels
Number of subjects: 0
Study 15845499 — intervention group
Group type: EXPERIMENTAL
Intervention: Children >/=2 years of age
Number of subjects: 0
Study 15845499 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who were 4 years of age
Number of subjects: 0
Study 11918735 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mmol/L lactate dialysate
Number of subjects: 8
Study 11918735 — intervention group
Group type: COMPARATOR
Intervention: 35 mmol/L lactate dialysate
Number of subjects: 8
Study 10342622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular Sm-153 PHYP combined with 40 mg triamcinolone hexacetonide
Number of subjects: 24
Study 10342622 — intervention group
Group type: COMPARATOR
Intervention: 40 mg intra-articular triamcinolone hexacetonide alone
Number of subjects: 24
Study 9196767 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 500 mg artemisinin with a single 500 mg oral dose of mefloquine (AM)
Number of subjects: 231
Study 9196767 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine therapy alone (M)
Number of subjects: 231
Study 1435916 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive measurement of pulse-amplitude ratio during Valsalva maneuver
Number of subjects: 34
Study 1435916 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive measurement of pulse-amplitude ratio
Number of subjects: 34
Study 3457047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% SnF2
Number of subjects: 437
Study 3457047 — intervention group
Group type: COMPARATOR
Intervention: 0.05% NaF
Number of subjects: 437
Study 30504097 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 144
Study 30504097 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (sham intervention)
Number of subjects: 144
Study 29421012 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction
Number of subjects: 1327
Study 29421012 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 myocardial infarction
Number of subjects: 1327
Study 29421012 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall myocardial infarction events
Number of subjects: 1327
Study 29421012 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin increase >10× the upper limit of normal
Number of subjects: 1327
Study 29421012 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 1327
Study 27806060 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Smoke‐Free Homes intervention delivered by trained 2‐1‐1 information and referral specialists (3 mailings and 1 coaching call)
Number of subjects: 500
Study 27806060 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Smoke‐Free Homes intervention
Number of subjects: 500
Study 27806060 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study 24206527 — intervention group
Group type: EXPERIMENTAL
Intervention: Laropiprant 40mg, clopidogrel 75mg, and aspirin 80mg (Study 1) or 81mg (Study 2) once daily for 7 days
Number of subjects: 0
Study 24206527 — intervention group
Group type: COMPARATOR
Intervention: Placebo, clopidogrel 75mg, and aspirin 80mg (Study 1) or 81mg (Study 2) once daily for 7 days
Number of subjects: 0
Study 23043882 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Fillapex and gutta percha
Number of subjects: 51
Study 23043882 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 51
Study 23043882 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus and gutta percha
Number of subjects: 51
Study 20889603 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom diary group (daily use for 14 days)
Number of subjects: 40
Study 20889603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diary use)
Number of subjects: 40
Study 18552684 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol antibiotic (AA)
Number of subjects: 43
Study 18552684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (aerosol saline)
Number of subjects: 43
Study 15876307 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (oral glucocorticoid), 1 dose per day for 2 weeks
Number of subjects: 0
Study 15876307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15876307 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen inhalation
Number of subjects: 0
Study 12499279 — intervention group
Group type: EXPERIMENTAL
Intervention: High EGFR-expressing HNSCCs (>median MOD)
Number of subjects: 155
Study 12499279 — intervention group
Group type: COMPARATOR
Intervention: Low EGFR-expressing HNSCCs
Number of subjects: 155
Study 10087548 — intervention group
Group type: EXPERIMENTAL
Intervention: CapSure Z leads (1.2 mm2 surface area; steroid-eluting)
Number of subjects: 188
Study 10087548 — intervention group
Group type: COMPARATOR
Intervention: CapSure SP leads (5.8 mm2 surface area; steroid-eluting)
Number of subjects: 188
Study 10087548 — intervention group
Group type: COMPARATOR
Intervention: CapSure leads (8 mm2 surface area; steroid-eluting)
Number of subjects: 188
Study 10087548 — intervention group
Group type: COMPARATOR
Intervention: Target Tip leads (8 mm2 surface area; no steroid elution)
Number of subjects: 188
Study 7723402 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of recombinant human granulocyte‐macrophage colony‐stimulating factor (rhGM‐CSF) 5 micrograms/kg/day
Number of subjects: 0
Study 7723402 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of rhGM‐CSF administered subcutaneously every 24 h
Number of subjects: 0
Study 8225680 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine HCl capsules (Minobese Forte)
Number of subjects: 21
Study 8225680 — intervention group
Group type: COMPARATOR
Intervention: Phentermine base capsules (Duromine)
Number of subjects: 21
Study 2858707 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass screening with single-view mammography every 2 or 3 years depending on age
Number of subjects: 134867
Study 2858707 — intervention group
Group type: COMPARATOR
Intervention: Control group (not offered screening)
Number of subjects: 134867
Study 2858707 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass screening with single-view mammography
Number of subjects: 134867
Study 31951263 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group (n = 80) receiving one-on-one physical therapy 8 times over 6 weeks and daily home exercises with wearable sensors
Number of subjects: 160
Study 31951263 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (n = 80) receiving the same intervention after a 6- to 8-week wait period with wearable sensors
Number of subjects: 160
Study 29122571 — intervention group
Group type: EXPERIMENTAL
Intervention: 360º video using Samsung GearVR virtual-reality headsets
Number of subjects: 40
Study 29122571 — intervention group
Group type: COMPARATOR
Intervention: 2D video on a 75-inch television
Number of subjects: 40
Study 24165269 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (4 sessions over 12 months)
Number of subjects: 430
Study 24165269 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 430
Study 21897113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric low glycemic index (LGI) diet (GI:60)
Number of subjects: 22
Study 21897113 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric high glycemic index (HGI) diet (GI:90)
Number of subjects: 22
Study 20713790 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of methylprednisolone
Number of subjects: 306
Study 20713790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 306
Study 18622294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis followed by preemptive therapy (ganciclovir for 30 days, then preemptive therapy with virologic monitoring)
Number of subjects: 21
Study 18622294 — intervention group
Group type: COMPARATOR
Intervention: Preemptive therapy alone (initiated at 100,000 DNA copies/mL whole blood)
Number of subjects: 21
Study 18622294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (prophylaxis and preemptive therapy)
Number of subjects: 21
Study 16001108 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg b.i.d.)
Number of subjects: 25
Study 16001108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12450909 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg elemental Zn/d)
Number of subjects: 301
Study 12450909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 10614677 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg/day continuously
Number of subjects: 165
Study 10614677 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol 50 mg/day continuously
Number of subjects: 165
Study 10614677 — intervention group
Group type: COMPARATOR
Intervention: Nontreated control group
Number of subjects: 165
Study 7864416 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl infusion (2 micrograms/mL at 4‐10 mL/h)
Number of subjects: 20
Study 7864416 — intervention group
Group type: COMPARATOR
Intervention: IV morphine via patient-controlled analgesia (IV‐PCA)
Number of subjects: 20
Study 7864416 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl infusion
Number of subjects: 20
Study 7864416 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl infusion and IV morphine via PCA
Number of subjects: 20
Study 2042178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraderma wheals (sterile water)
Number of subjects: 268
Study 2042178 — intervention group
Group type: COMPARATOR
Intervention: Dry needling
Number of subjects: 268
Study 2042178 — intervention group
Group type: COMPARATOR
Intervention: Control group (perinatal complications)
Number of subjects: 268
Study 7191614 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 and E3 orally in doses of 4-8 mg per day for 3 weeks
Number of subjects: 30
Study 7191614 — intervention group
Group type: COMPARATOR
Intervention: Gestagen (1000 mg i.m. injection)
Number of subjects: 30
Study 31039180 — intervention group
Group type: EXPERIMENTAL
Intervention: Walkasins ON
Number of subjects: 31
Study 31039180 — intervention group
Group type: COMPARATOR
Intervention: Walkasins OFF
Number of subjects: 31
Study 31039180 — intervention group
Group type: EXPERIMENTAL
Intervention: Walkasins OFF-then-ON
Number of subjects: 31
Study 31039180 — intervention group
Group type: COMPARATOR
Intervention: Walkasins ON-then-OFF
Number of subjects: 31
Study 31039180 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Functional Gait Assessment
Number of subjects: 31
Study 31039180 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal fall-risk status
Number of subjects: 31
Study 28544029 — intervention group
Group type: EXPERIMENTAL
Intervention: True RIII feedback in chronic back pain subjects (n=18)
Number of subjects: 33
Study 28544029 — intervention group
Group type: COMPARATOR
Intervention: Sham RIII feedback in chronic back pain subjects (n=15)
Number of subjects: 33
Study 28544029 — intervention group
Group type: EXPERIMENTAL
Intervention: True RIII feedback in healthy control subjects (n=15)
Number of subjects: 33
Study 25732567 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood NMR assessed at Time-1 and Time-2 (2-3 weeks apart)
Number of subjects: 72
Study 25732567 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR categorized into slow (NMR ≤ 0.24) or normal/fast (NMR ≥ 0.25)
Number of subjects: 72
Study 25732567 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR quartiles classification
Number of subjects: 72
Study 24113039 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (200 µg/kg bolus, followed by 350 µg·kg(‐1)·h(‐1) i.v. infusion)
Number of subjects: 300
Study 24113039 — intervention group
Group type: COMPARATOR
Intervention: Heparin (100 U/kg via artery sheaths)
Number of subjects: 300
Study 24113039 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 300
Study 24113039 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 300
Study 21377804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) 24 IU
Number of subjects: 96
Study 21377804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 19906103 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-EGFR monoclonal antibody
Number of subjects: 4186
Study 19906103 — intervention group
Group type: COMPARATOR
Intervention: No anti-EGFR monoclonal antibody (Control)
Number of subjects: 4186
Study 17293063 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg L-selenomethionine daily for 6 months
Number of subjects: 0
Study 15510787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment in addition to routine diabetes treatment
Number of subjects: 80
Study 15510787 — intervention group
Group type: COMPARATOR
Intervention: Domperidone treatment in addition to routine diabetes treatment
Number of subjects: 80
Study 15510787 — intervention group
Group type: COMPARATOR
Intervention: No treatment in addition to routine diabetes treatment
Number of subjects: 80
Study 11578021 — intervention group
Group type: EXPERIMENTAL
Intervention: 300mg ASU
Number of subjects: 0
Study 11578021 — intervention group
Group type: EXPERIMENTAL
Intervention: 600mg ASU
Number of subjects: 0
Study 11578021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10023308 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU) + Leucovorin (LV)
Number of subjects: 439
Study 10023308 — intervention group
Group type: COMPARATOR
Intervention: Raltitrexed (Tomudex)
Number of subjects: 439
Study 7931490 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 5 micrograms/kg
Number of subjects: 184
Study 7931490 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms/kg
Number of subjects: 184
Study 7931490 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms/kg
Number of subjects: 184
Study 7931490 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 184
Study 2979273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg taken at 18.15 hours after a standard meal at 18.00 hours
Number of subjects: 9
Study 2979273 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg taken at 18.15 hours after a late meal at 22.00 hours
Number of subjects: 9
Study 29152675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation at 50,000 IU/week
Number of subjects: 40
Study 29152675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28107090 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus mFOLFOX6
Number of subjects: 0
Study 28107090 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus mFOLFOX6
Number of subjects: 0
Study 26038879 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm cooling between sets
Number of subjects: 0
Study 26038879 — intervention group
Group type: COMPARATOR
Intervention: No palm cooling
Number of subjects: 0
Study 26038879 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm cooling between sets and post-exercise
Number of subjects: 0
Study 23089512 — intervention group
Group type: EXPERIMENTAL
Intervention: TALK social worker intervention (video and booklet plus patient and family social worker visits)
Number of subjects: 130
Study 23089512 — intervention group
Group type: EXPERIMENTAL
Intervention: TALK education intervention (video and booklet)
Number of subjects: 130
Study 23089512 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine care with nephrologists)
Number of subjects: 130
Study 20647564 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 6921
Study 20647564 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 6921
Study 20647564 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 6921
Study 20647564 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic characteristics
Number of subjects: 6921
Study 20647564 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters
Number of subjects: 6921
Study 17370343 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening of consonant-vowel syllables /da/-/ba/ (true DL)
Number of subjects: 10
Study 17370343 — intervention group
Group type: COMPARATOR
Intervention: Dichotic listening of consonant-vowel syllables /da/-/ka/ (sham DL)
Number of subjects: 10
Study 16784030 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0
Study 12719279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) plus atorvastatin (10, 20, 40, or 80 mg)
Number of subjects: 628
Study 12719279 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10, 20, 40, or 80 mg)
Number of subjects: 628
Study 12719279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study 11256891 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised 9-month step-aerobic program (two sessions per week, each session complemented with additional jumps)
Number of subjects: 64
Study 11256891 — intervention group
Group type: COMPARATOR
Intervention: Control group (62 girls, 33 premenarcheal, 29 postmenarcheal)
Number of subjects: 64
Study 8994512 — intervention group
Group type: EXPERIMENTAL
Intervention: LY293111 (112 mg three times daily for seven days)
Number of subjects: 12
Study 8994512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1453314 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0
Study 1453314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 1453314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of chlorpheniramine and cimetidine
Number of subjects: 0
Study 1453314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3933202 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyoimmunogen vaccine
Number of subjects: 60
Study 3933202 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-P. aeruginosa plasma
Number of subjects: 60
Study 31174360 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% basal insulin dose
Number of subjects: 9
Study 31174360 — intervention group
Group type: COMPARATOR
Intervention: 100% basal insulin dose
Number of subjects: 9
Study 31174360 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trial arms (75% and 100% basal insulin)
Number of subjects: 9
Study 29106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated‐humidified gases
Number of subjects: 273
Study 29106924 — intervention group
Group type: COMPARATOR
Intervention: Unconditioned gases
Number of subjects: 273
Study 26797016 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol
Number of subjects: 389
Study 26797016 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium
Number of subjects: 389
Study 26797016 — intervention group
Group type: COMPARATOR
Intervention: Vilanterol
Number of subjects: 389
Study 24844026 — intervention group
Group type: EXPERIMENTAL
Intervention: Zucchelli's technique
Number of subjects: 20
Study 24844026 — intervention group
Group type: COMPARATOR
Intervention: Tunnel technique with subepithelial connective tissue graft (SECTG)
Number of subjects: 20
Study 22743744 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% buffered lidocaine
Number of subjects: 55
Study 22743744 — intervention group
Group type: COMPARATOR
Intervention: Sterile normal saline
Number of subjects: 55
Study 19709787 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.8 g/d of plant stanols as esters
Number of subjects: 49
Study 19709787 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 49
Study 17408407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet inflation (Ti; n = 12)
Number of subjects: 24
Study 17408407 — intervention group
Group type: COMPARATOR
Intervention: No pneumatic tourniquet inflation (Tn; n = 12)
Number of subjects: 24
Study 16061711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg 8 hourly for 12 weeks (n = 9)
Number of subjects: 22
Study 16061711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg 8 hourly for 12 weeks (n = 5)
Number of subjects: 22
Study 16061711 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 22
Study 12429323 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydimethylsiloxane (Macroplastique)
Number of subjects: 114
Study 12429323 — intervention group
Group type: COMPARATOR
Intervention: Dextranomer/hyaluronic acid copolymer (Deflux)
Number of subjects: 114
Study 10335994 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed RBC units stored for 42 days
Number of subjects: 44
Study 10335994 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet components transfused to 25 patients
Number of subjects: 44
Study 8944004 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (4DFR)
Number of subjects: 303
Study 8944004 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (FFQ)
Number of subjects: 303
Study 1826370 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 8
Study 1826370 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (200 mg/day for 4 days)
Number of subjects: 8
Study 6123337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.05 mg kg‐1
Number of subjects: 199
Study 6123337 — intervention group
Group type: COMPARATOR
Intervention: Trimeprazine 3 mg kg‐1
Number of subjects: 199
Study 31351449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention including 'My Knee Exercise' website and 24-week behaviour change SMS exercise adherence program
Number of subjects: 206
Study 31351449 — intervention group
Group type: COMPARATOR
Intervention: Education control website 'My Knee Education' containing OA and exercise information only
Number of subjects: 206
Study 31351449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 206
Study 31351449 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 206